Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer

Gan, Xia; Wang, Ting; Chen, Zhiyong; Zhang, Kun‐He

doi:10.1007/s11033-020-05838-0

Cited by 12 publications

(8 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These biomarkers are detected in blood-based protein quantification tests or with immunohistochemistry [ 3 , 4 ]. Locally advanced malignant lesions enhance the level of circulating nucleic acids by up to 15-fold, the concentration in patients with metastatic cancers reaching up to 500 ng/mL [ 3 ].…”

Section: Blood Biomarkersmentioning

confidence: 99%

Novel Diagnostic Biomarkers in Colorectal Cancer

Zygulska¹,

Pierzchalski

2022

IJMS

133

View full text Add to dashboard Cite

Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease associated with a number of genetic or somatic mutations. Diagnostic markers are used for risk stratification and early detection, which might prolong overall survival. Nowadays, the widespread use of semi-invasive endoscopic methods and feacal blood tests characterised by suboptimal accuracy of diagnostic results has led to the detection of cases at later stages. New molecular noninvasive tests based on the detection of CRC alterations seem to be more sensitive and specific then the current methods. Therefore, research aiming at identifying molecular markers, such as DNA, RNA and proteins, would improve survival rates and contribute to the development of personalized medicine. The identification of “ideal” diagnostic biomarkers, having high sensitivity and specificity, being safe, cheap and easy to measure, remains a challenge. The purpose of this review is to discuss recent advances in novel diagnostic biomarkers for tumor tissue, blood and stool samples in CRC patients.

show abstract

Section: Blood Biomarkersmentioning

confidence: 99%

Novel Diagnostic Biomarkers in Colorectal Cancer

Zygulska¹,

Pierzchalski

2022

IJMS

133

View full text Add to dashboard Cite

show abstract

“…Cancer is a complex and heterogeneous disease, rarely detected at its initial stages [1] . Current methods rely on biomarker panels that contain several genes rather than a single specific biomarker to quickly and accurately detect cancers [2] , [3] , [4] . The advent of high-throughput technologies, such as whole/targeted exome sequencing, whole-genome sequencing, large-scale RNA sequencing, and chromatin immunoprecipitation followed by sequencing (ChIP-Seq) and mass spectrometry-based proteomics, has accelerated cancer research and has resulted in a large volume of publicly available data.…”

Section: Introductionmentioning

confidence: 99%

UALCAN: An update to the integrated cancer data analysis platform

et al. 2022

View full text Add to dashboard Cite

Cancer genomic, transcriptomic, and proteomic profiling has generated extensive data that necessitate the development of tools for its analysis and dissemination. We developed UALCAN to provide a portal for easy exploring, analyzing, and visualizing these data, allowing users to integrate the data to better understand the gene, proteins, and pathways perturbed in cancer and make discoveries. UALCAN web portal enables analyzing and delivering cancer transcriptome, proteomics, and patient survival data to the cancer research community. With data obtained from The Cancer Genome Atlas (TCGA) project, UALCAN has enabled users to evaluate protein-coding gene expression and its impact on patient survival across 33 types of cancers. The web portal has been used extensively since its release and received immense popularity, underlined by its usage from cancer researchers in more than 100 countries. The present manuscript highlights the task we have undertaken and updates that we have made to UALCAN since its release in 2017. Extensive user feedback motivated us to expand the resource by including data on a) microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and promoter DNA methylation from TCGA and b) mass spectrometry-based proteomics from the Clinical Proteomic Tumor Analysis Consortium (CPTAC). UALCAN provides easy access to pre-computed, tumor subgroup-based gene/protein expression, promoter DNA methylation status, and Kaplan-Meier survival analyses. It also provides new visualization features to comprehend and integrate observations and aids in generating hypotheses for testing. UALCAN is accessible at http://ualcan.path.uab.edu

show abstract

“…High-throughput next-generation sequencing is a genomic technique for sequencing an organism’s DNA [ 31 ]. Multiple- biomarker panels are usually more sensitive than single biomarkers, as demonstrated by many research studies over the last few years [ 32 ]. For illustration, Ghatak S et al used differential gene expression analysis in five independent in silico CRC cohorts and immunohistochemistry in one clinical cohort to validate their results.…”

Section: Genomics Of Crcmentioning

confidence: 99%

Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives

Ullah

Yang

Yin

et al. 2022

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is common Cancer as well as the third leading cause of mortality around the world; its exact molecular mechanism remains elusive. Although CRC risk is significantly correlated with genetic factors, the pathophysiology of CRC is also influenced by external and internal exposures and their interactions with genetic factors. The field of CRC research has recently benefited from significant advances through Omics technologies for screening biomarkers, including genes, transcripts, proteins, metabolites, microbiome, and lipidome unbiasedly. A promising application of omics technologies could enable new biomarkers to be found for the screening and diagnosis of CRC. Single-omics technologies cannot fully understand the molecular mechanisms of CRC. Therefore, this review article aims to summarize the multi-omics studies of Colorectal cancer, including genomics, transcriptomics, proteomics, microbiomics, metabolomics, and lipidomics that may shed new light on the discovery of novel biomarkers. It can contribute to identifying and validating new CRC biomarkers and better understanding colorectal carcinogenesis. Discovering biomarkers through multi-omics technologies could be difficult but valuable for disease genotyping and phenotyping. That can provide a better knowledge of CRC prognosis, diagnosis, and treatments.

show abstract

Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer

Cited by 12 publications

References 77 publications

Novel Diagnostic Biomarkers in Colorectal Cancer

Novel Diagnostic Biomarkers in Colorectal Cancer

UALCAN: An update to the integrated cancer data analysis platform

Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives

Contact Info

Product

Resources

About